Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms

Autor: Xiao Chen, Chuangen Guo, Yajie Wang, Xiaoling Zhuge
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Adult
Blood Glucose
Male
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
high-density lipoprotein
Logistic regression
Gastroenterology
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Prediabetic State
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
High-density lipoprotein
Endocrinology
tumor grade
Diabetes mellitus
Internal medicine
medicine
fasting plasma glucose
Humans
Risk factor
Insulinoma
Pathological
Original Research
Aged
Retrospective Studies
lcsh:RC648-665
business.industry
pancreatic neuroendocrine neoplasms
Fasting
Middle Aged
medicine.disease
Impaired fasting glucose
Pancreatic Neoplasms
Neuroendocrine Tumors
030104 developmental biology
Cross-Sectional Studies
chemistry
030220 oncology & carcinogenesis
diabetes mellitus
Female
business
Lipoprotein
Zdroj: Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 11 (2020)
ISSN: 1664-2392
Popis: ObjectiveDiabetes mellitus (DM) is probably a risk factor for pancreatic neuroendocrine neoplasms (PNENs). However, the prevalence of DM in PNEN patients remains inconclusive. In the present study we observed the prevalence of DM and possible risk factors in PNEN patients.MethodsAfter excluding those with insulinoma, a total of 197 patients with PNENs were included. The demographic data, pathological characteristics, and data of blood biochemical tests were recorded. DM was considered if there was evidence of a fasting plasma glucose level of ≥7.0 mmol/L or a 2-h plasma glucose level of ≥11.1 mmol/L, or a history of DM at the time of PNEN diagnosis. Impaired fasting glucose was considered if fasting plasma glucose level was between 6.1 and 7.0 mmol/L.ResultsThe prevalence of DM, new-onset DM, and impaired fasting glucose were 17.26, 9.14, and 7.1%, respectively. The prevalence of DM was 26.0% in patients ≥60 years old (19/73) and 12.1% in patients ConclusionOur data shows that the prevalence of DM is 17.26% in patients with PNENs and is 26.0% in patients ≥60 years of age after excluding insulinoma. Age, nerve invasion, tumor size, and HDL are risk factors for DM in PNEN patients.
Databáze: OpenAIRE
Externí odkaz: